Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1995 1
1998 2
2000 1
2001 4
2002 4
2003 7
2004 2
2005 3
2006 4
2007 12
2008 10
2009 7
2010 8
2011 9
2012 10
2013 12
2014 10
2015 7
2016 6
2017 10
2018 7
2019 9
2020 12
2021 8
2022 11
2023 10
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828951 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Armand P, et al. Among authors: gulbas z. J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609651 Free PMC article. Clinical Trial.
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Birtas Atesoglu E, et al. Among authors: gulbas z. Hematol Oncol. 2023 Oct;41(4):663-673. doi: 10.1002/hon.3174. Epub 2023 May 22. Hematol Oncol. 2023. PMID: 37211991
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: gulbas z. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, Castilla-Llorente C, Kröger N, Eder M, Rambaldi A, Bonifazi F, Blau IW, Stelljes M, Dreger P, Moiseev I, Schoemans H, Koenecke C, Peric Z. Penack O, et al. Among authors: gulbas z. Blood Cancer J. 2024 Mar 15;14(1):45. doi: 10.1038/s41408-024-01032-8. Blood Cancer J. 2024. PMID: 38485723 Free PMC article.
Aging and blood disorders: new perspectives, new challenges.
Bron D, Ades L, Fulop T, Goede V, Stauder R; Elderly Task Force in Hematology EHA SWG. Bron D, et al. Haematologica. 2015 Apr;100(4):415-7. doi: 10.3324/haematol.2015.126771. Haematologica. 2015. PMID: 25828087 Free PMC article. No abstract available.
Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas.
Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H Sr, Boumendil A Sr, Glass B, Castagna L, Dominietto A, McGuirk J, Blaise D, Gülbas Z, Diez-Martin J, Marsh SGE, Paczesny S, Gadalla SM, Dreger P, Zhang MJ, Spellman SR, Lee SJ, Bolon YT, Sureda A. Mussetti A, et al. Among authors: gulbas z. Transplant Cell Ther. 2023 Mar;29(3):184.e1-184.e9. doi: 10.1016/j.jtct.2022.11.028. Epub 2022 Dec 25. Transplant Cell Ther. 2023. PMID: 36577482 Free PMC article.
167 results